The Stem for Life Foundation, NeoStem, Inc. (NYSE MKT:NBS), The
Pontifical Council for Culture, and STOQ International today
released details on the program of The Second International Vatican
Adult Stem Cell Conference: Regenerative Medicine — A Fundamental
Shift in Science & Culture, taking place from within The
Vatican, April 11-13, 2013.
This event is part of a five-year collaboration between The Stem
for Life Foundation, a not-for-profit organization devoted to
raising global awareness of the therapeutic potential of adult stem
cells, NeoStem, a leader in the emerging cellular therapy industry,
The Vatican's Pontifical Council for Culture and its foundation,
called STOQ International (Science, Theology and the Ontological
Quest).
"Regenerative medicine is poised to revolutionize disease
management by finding new ways to boost the body's ability to heal
itself. Whereas today, treatment for many diseases is a matter of
managing symptoms, regenerative medicine seeks to reverse the
course of the disease by targeting its cause and repairing diseased
or defective tissues or organs," said Dr. Robin Smith, President of
The Stem for Life Foundation and CEO of NeoStem. "This conference
brings together a notable group of adult stem cell researchers,
educators, policy experts, ethicists, patients, and religious
officials."
The goals of the 2013 Second International Vatican Adult Stem
Cell Conference are to:
- Foster an open dialogue amongst researchers, physicians,
philanthropists, faith leaders and policy-makers in order to help
identify clear, unmet medical needs throughout the world that can
be addressed through the development of cellular therapies that
will reduce human suffering.
- Expand global awareness of the here-and-now opportunities of
adult stem cell therapies, reducing misperceptions surrounding the
field of cellular research.
- Lay the groundwork for a collaborative network of scientists,
educators and patrons who embrace the promise of adult stem cells,
creating an array of subsequent educational events at leading
universities and institutions throughout the world, inspiring the
next generation of cellular researchers.
The conference will be moderated by Meredith Vieira from NBC
News, Bill Hemmer from The Fox News Channel, and Dr. Max Gomez from
WCBS-TV. Highlights of the conference will include:
- Hope for the future of adult stem cell therapy for multiple
sclerosis ("MS"), featuring Richard M. Cohen, journalist and
husband of Ms. Vieira, Dr. Richard Burt of Northwestern University,
Dr. Saud Sadiq of the MS Research Center of New York, and multiple
sclerosis patients who participated in clinical trials and have
been successfully treated with adult stem cells. We will also
take a look at Tcelna™, Opexa Therapeutics (Nasdaq:OPXA)
T-cell immunotherapy in development for secondary progressive
multiple sclerosis.
- Keynote speech by Dr. John Gurdon, 2012 Nobel Prize Winner for
Physiology or Medicine for his work on transforming adult cells
into stem cells.
- Overview of contemporary stem cell transplants and current
research for the treatment of cancer and osteogenesis
imperfecta with field experts, featuring Dr. Edwin Horwitz of
Children's Hospital of Philadelphia (UPENN), Dr. Stephen Nimer of
the Sylvester Comprehensive Cancer Center, and Dr. Amitabha
Mazumder of the NYU Clinical Cancer Center.
- An in-depth look at many of the companies, such as NeoStem,
Athersys (Nasdaq:ATHX), and Mesoblast (ASX:MSB) (USOTC:MBLTY),
making progress in developing adult stem cell therapies for
cardiovascular disease.
- A dynamic panel on the politics, perceptions and promise of
cell therapies, moderated by Peggy Noonan of The Wall Street
Journal and featuring former U.S. Health and Human Services
Secretary and Governor, Tommy G. Thompson, former U.S. Senator,
Norm Coleman, former member of the President's Council on
Bioethics, William Hurlbut, and University College London Professor
of Regenerative Medicine Bioprocessing, Chris Mason.
- Sessions on developments in cellular therapies for organ and
tissue repair and diabetes, as well as on the potential to use
stem cells to treat traumatic brain injury and other
neurodegenerative diseases. We will discuss differences among adult
stem cells and learn about exciting work on the potential to use
placental stem cells to treat autoimmune diseases.
- We will hear from Dr. Robert Preti, President and Chief
Scientific Officer of Progenitor Cell Therapy (PCT), on how to turn
an adult stem cell into a therapy.
- The story of Osiris Therapeutics' (Nasdaq:OSIR) successful
approval of an adult stem cell therapy in Canada and elsewhere for
graft-vs-host disease, Prochymal®, with Osiris CEO, Dr. C. Randal
Mills.
- There will also be discussion about education, faith, and
science with respect to a future with cellular therapy by Dr.
Phillip Sloan (University of Notre Dame) and Rev. Nicanor Pier
Giorgio Austriaco, O.P. (Providence College), as well as discussion
around the social and cultural considerations by Dr. Malik Hasan,
Founder of Qual-Med, consideration of the moral and ethical
implications of adult stem cell research, and consideration of how
to prepare the future generation of leaders and scholars by Dr.
Anthony J. Cernera, President of the Center for Interreligious
Understanding.
- Panel discussions will look at the new frontiers of cellular
research pertaining to stem cells, health, longevity and
epigenetics. We will examine the ties between stem cell health and
aging and hear from experts in the field, including Dr. Vincent
Giampapa (University of Medicine and Dentistry, New Jersey), Dr.
Ronald DePinho (University of Texas MD Anderson Cancer Center), Dr.
Wayne A. Marasco (Dana-Farber Cancer Institute), and Dr. Mariusz Z.
Ratajczak (University of Louisville). Dr. Valter Longo (University
of Southern California, Davis), Dr. Jaime Guevara-Aguirre
(Institute of Endocrinology, Quito, Ecuador), and Dr. Nir
Barzilai (Albert Einstein College of Medicine) will look at
fascinating case studies on longevity and disease resistance,
including a unique look at 'Laron dwarfs' and their absence of
cancer and chronic disease.
Some corporate sponsors of the conference include NeoStem,
Mesoblast, Celgene (Nasdaq:CELG), Opexa Therapeutics, Lowenstein
Sandler, Aspire Capital Partners, Kenyon & Kenyon, and the
Maxim Group. Major support also comes from philanthropists who
believe in the promise of adult stem cells. To learn more about The
Second International Vatican Adult Stem Cell Conference please
visit www.adultstemcellconference.org.
About The Pontifical Council for Culture
The Pontifical Council for Culture is that Dicastery of the
Roman Curia which assists the Pope in the exercise of his supreme
pastoral office for the benefit and service of the universal Church
and of particular Churches concerning the encounter between the
saving message of the Gospel and cultures, in the study of the
weighty phenomena of the rift between the Gospel and cultures;
indifference in matters of religion; unbelief. It is also concerned
with relationships between the Church and the Holy See and the
world of culture; in particular it promotes dialogue with
contemporary cultures, so that human civilization may become
increasingly open to the Gospel, and so that men and women of
science, letters and the arts may know that the Church acknowledges
their work as a service to truth, goodness and beauty.
www.cultura.va
About STOQ International
STOQ International is a non-profit 501(c)3 tax-exempt
organization operating in the U.S. for the purpose of creating
important dialogue between the Church and contemporary culture,
which is strongly shaped by scientific advancements.
Its aim is to change the debate in the arena of ideas related to
Theology, Philosophy and present-day Science, through supporting
and encouraging scientific research, educational programs and
cultural initiatives. The alliance of experts from the disciplines
of science, theology and philosophy that form the STOQ Project
provokes a renewal of thinking about God and man, creation and
providence. STOQ International wants thus to challenge the public
perception of the relationship between the Church tradition and
science, and we prove the compatibility of faith and reason in the
pursuit of knowledge.
The purpose of STOQ is to endorse and conduct an
interdisciplinary dialogue in order to build a culture that
promotes the full dignity of humanity. The main mission of STOQ is
to build a bridge between science and theology, providing for their
positive impact on contemporary society, as well as to support
studies through joint research projects, conferences and
educational & cultural enterprises.
To know more about STOQ, please visit:
www.stoqinternational.com
About The Stem for Life Foundation
The Stem for Life Foundation (SFLF) is dedicated to improving
the quality of life of millions of people suffering from dozens of
painful and sometimes debilitating medical conditions by providing
information and updates about adult stem cell research, therapy
development and possible healthcare applications. SFLF focuses on
educating the public, convening the best minds in adult stem cell
medicine and research, supporting clinical research, and
subsidizing adult stem cell collection and storage for those who
need it most.
Understanding that adult stem cell research could lead to better
treatments and possibly cures for chronic disease, as well as
reduce health care costs and improve quality of life for those with
chronic disease and disability, SFLF was established in 2007.
SFLF's Board of Trustees and staff are deeply committed to
expediting development of stem cell therapies that offer real hope
to individuals suffering from a wide-range of life-threatening
medical conditions.
For more information on the Stem for Life Foundation, please
visit http://www.stemforlife.org
About NeoStem, Inc.
NeoStem, Inc. (the "Company") is a leader in the emerging
cellular therapy industry. Our business model includes the
development of novel proprietary cell therapy products as well as
operating a contract development and manufacturing organization
("CDMO") providing services to others in the regenerative medicine
industry. The combination of a therapeutic development business and
revenue-generating service provider business provides the Company
with capabilities for cost effective in-house product development
and immediate revenue and cash flow generation. www.neostem.com
Forward-Looking Statements for NeoStem,
Inc.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the successful execution of the
Company's business strategy, including with respect to the
Company's or its partners' successful development of AMR-001 and
other cell therapeutics, the size of the market for such products,
its competitive position in such markets, the Company's ability to
successfully penetrate such markets and the market for its contract
development and manufacturing business, and the efficacy of
protection from its patent portfolio, as well as the future of the
cell therapeutics industry in general, including the rate at which
such industry may grow. The Company's actual results could differ
materially from those anticipated in these forward- looking
statements as a result of various factors, including but not
limited to matters described under the "Risk Factors" in the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 11, 2013 and in the Company's other
periodic filings with the Securities and Exchange Commission, all
of which are available on its website. The Company does not
undertake to update its forward-looking statements. The Company's
further development is highly dependent on future medical and
research developments and market acceptance, which is outside its
control.
CONTACT: Todd Aydelotte, Managing Director
Allison+Partners
Phone: +1-646-428-0644
Email: todd@allisonpr.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2024 to May 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From May 2023 to May 2024